Difference between revisions of "Part:BBa K2549005"

 
Line 3: Line 3:
 
<partinfo>BBa_K2549005 short</partinfo>
 
<partinfo>BBa_K2549005 short</partinfo>
  
−
Anti-CD19(&#945;CD19) is a CD19 scFv. Its heavy-chain variable region(&#945;CD19a) and light-chain variable region(&#945;CD19b) are fused using a glycine-rich peptide linker(3 repeats of GGGGS, or G4S). It can be served as the extracellular domain of the SynNotch, thus accomplishing the contact-dependent signal input against CD19.  
+
Anti-CD19(&#945;CD19) is a CD19 scFv. Its heavy-chain variable region(&#945;CD19a) and light-chain variable region(&#945;CD19b) are fused using a glycine-rich peptide linker(3 repeats of GGGGS, or G4S)[1]. It can be served as the extracellular domain of the SynNotch, thus accomplishing the contact-dependent signal input against CD19.  
  
 
<!-- Add more about the biology of this part here
 
<!-- Add more about the biology of this part here
Line 12: Line 12:
 
<partinfo>BBa_K2549005 SequenceAndFeatures</partinfo>
 
<partinfo>BBa_K2549005 SequenceAndFeatures</partinfo>
  
 +
===References===
 +
[1]Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia; Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia; Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. . N Engl J Med, 2016 Mar;374(10):998 PMID: 26962747; DOI: 10.1056/NEJMx160005
  
 
<!-- Uncomment this to enable Functional Parameter display  
 
<!-- Uncomment this to enable Functional Parameter display  

Revision as of 11:37, 6 October 2018


anti-CD19

Anti-CD19(αCD19) is a CD19 scFv. Its heavy-chain variable region(αCD19a) and light-chain variable region(αCD19b) are fused using a glycine-rich peptide linker(3 repeats of GGGGS, or G4S)[1]. It can be served as the extracellular domain of the SynNotch, thus accomplishing the contact-dependent signal input against CD19.

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    INCOMPATIBLE WITH RFC[1000]
    Illegal BsaI site found at 444

References

[1]Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia; Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia; Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. . N Engl J Med, 2016 Mar;374(10):998 PMID: 26962747; DOI: 10.1056/NEJMx160005